Revenue: The sum of all revenue fields included for a company's operating activities.
Avalo Therapeutics, Inc. (AVTX) had Revenue of $0.44M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
|
Revenue |
$0.44M |
$-35.13M |
|
$-0.37M |
|
$0.81M |
|
$68.95M |
|
$-68.51M |
|
$33.50M |
|
$-35.02M |
|
$-35.02M |
|
$-35.13M |
|
$-35.13M |
|
$-35.13M |
|
$-35.13M |
|
$-68.51M |
|
$-68.34M |
|
4.43M |
|
7.50M |
|
$-7.94 |
|
$-20.91 |
|
| Balance Sheet Financials | |
$138.89M |
|
$1.21M |
|
$11.84M |
|
$150.73M |
|
$6.96M |
|
-- |
|
$10.74M |
|
$17.70M |
|
$133.03M |
|
$122.53M |
|
$133.03M |
|
10.47M |
|
| Cash Flow Statement Financials | |
$-49.06M |
|
$0.36M |
|
$175.85M |
|
$7.55M |
|
$134.70M |
|
$127.15M |
|
$5.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.96 |
|
-- |
|
-- |
|
-- |
|
-- |
|
182.99% |
|
-15535.60% |
|
-15535.60% |
|
-15497.28% |
|
-7939.91% |
|
-7965.76% |
|
$-49.06M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.72 |
|
505.70 |
|
-26.41% |
|
-28.67% |
|
-23.31% |
|
-26.41% |
|
$12.70 |
|
$-6.54 |
|
$-6.54 |
|